首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1169176

皮肌炎治疗市场：按药物类型、给药途径、分销渠道、地区 - 规模、份额、展望、机会分析，2022-2030 年

Dermatomyositis Drug Market, by Drug Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年11月08日 | 出版商:

Coherent Market Insights | 英文 166 Pages | 商品交期: 2-3个工作天内

价格

简介目录

皮肌炎 (DM) 是一种罕见的炎症性肌肉疾病，不仅会影响肌肉，还会影响皮肤。皮肌炎影响所有种族、性别和年龄的人。它在儿童时期对男性和女性的影响相同，但在成年女性中更为常见。 DM 的确切原因尚不清楚，但据信是由遗传易感个体的外部因素（例如，恶性肿瘤、药物、传染源类型）引发的免疫介导过程引起的。皮肌炎可能与其他结缔组织病并存，如係统性红斑狼疮、类风湿性关节炎、硬皮病、干燥综合征和混合性结缔组织病。

市场动态

全球皮肌炎治疗市场的主要参与者正专注于采用产品批准等增长战略，这些战略有望在预测期内推动市场增长。例如，2018 年 7 月，专注于开发和商业化治疗罕见、慢性和严重炎症和纤维化疾病的新型疗法的 3 期临床阶段製药公司 Corbus Pharmaceuticals Holdings 宣布，美国食品和药物管理局已批准孤儿药指定其新型合成口服内源性大麻素模拟物 lenabasum，用于治疗皮肌炎。此外，主要参与者增加治疗皮肌炎的研发活动预计将在预测期内推动市场增长。例如，2019年10月21日，生物製药公司CSL Behring启动了评估IgPro20（皮下免疫球蛋白，Hizentra）在成人皮肌炎（DM）中的疗效、安全性和药代动力学的3期研究，并开始了试验。该试验计划于 2024 年 2 月结束。

研究的主要特点

本报告对全球皮肌炎药物市场进行了深入分析，包括以 2021 年为基准年的预测期（2022-2030 年）的市场规模（百万美元）和復合年增长率 (CAGR%)。 ) 提供。
解释了不同细分市场的潜在创收机会，并描述了针对该市场的有吸引力的投资建议矩阵。
它还提供了有关市场驱动因素和製约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争战略的重要见解。
根据以下参数对全球皮肌炎治疗市场的主要参与者进行了介绍 - 公司概况、产品组合、主要亮点、财务业绩和战略。
本研究涵盖的主要公司包括辉瑞公司、Teva Pharmaceuticals USA, Inc.、Hikma Pharmaceuticals PLC、Asahi Kasei Corporation.、Octapharma USA、Healthcare Pharmaceuticals Limited.、Zydus Cadila、Alkem Laboratories Ltd、Apotex Inc.、礼来公司和 F. Hoffman-La Roche Ltd
这份报告中的见解将使企业营销人员和高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
《全球皮肌炎药物市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
利益相关者可以通过用于分析全球皮肌炎药物市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

调查目的
先决条件
缩写说明

第二章市场展望

报告内容
- 市场定义和范围
执行摘要
- 市场概况：按药物类型
- 按给药途径划分的市场概况
- 市场概况：按分销渠道
- 市场概况：按地区
连贯机会图 (COM)

第3章市场动态、规律及趋势分析

市场动态
- 司机
- 约束因素
- 商机
影响分析
监管场景
市场趋势
主要发展状况
流行病学
害虫分析
合作研究和收购
搬运工分析
管道分析

第 4 章全球皮肌炎治疗市场 - 冠状病毒 (COVID-19) 大流行的影响

对经济的影响
对供需的影响
COVID-19 影响评估

第 5 章按药物类型分列的皮肌炎药物全球市场，2017-2030

肾上腺皮质类固醇
免疫抑製剂
其他

第 6 章。全球皮肌炎治疗市场：按给药途径，2017-2030

口服剂
局部管理
其他

第 7 章。全球皮肌炎治疗药物市场：按分销渠道，2017-2030

医院药房
零售药房
在线药店

第 8 章。全球皮肌炎治疗市场：按地区划分，2017-2030

北美
美国
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地区
欧洲
英国
德国
法国
意大利
西班牙
俄罗斯
其他欧洲
亚太地区
中国
印度
日本
澳大利亚
韩国
东盟
其他亚太地区
中东
海湾合作委员会
以色列
其他中东地区
非洲
北非
中非
南非

第9章竞争格局

热图分析
市场份额分析
- Pfizer Inc.
- Teva Pharmaceuticals USA, Inc.
- Hikma Pharmaceuticals PLC
- Asahi Kasei Corporation.
- Octapharma USA
- Healthcare Pharmaceuticals Limited.
- Zydus Cadila
- Alkem Laboratories Ltd
- Apotex Inc
- Eli Lilly and Co
- Hoffman-La Roche Ltd

第 10 章

调查方法介绍
关于出版商

简介目录

Product Code: CMI5333

Dermatomyositis (DM) is a rare inflammatory muscle disease that affects both the muscles as well as the skin. Dermatomyositis can strike people of all races, genders, and ages. Although, both males and females are affected equally in childhood, it is more common in females in adults. The exact cause of DM is unknown but it is believed to result from an immune-mediated process triggered by outside factors (e.g. malignancy, drugs, and infectious Drug Types) in genetically predisposed individuals. Dermatomyositis can occur with other connective tissue disorders such as systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren's syndrome, and mixed connective tissue disease.

Market Dynamics

Key players operating in the global dermatomyositis drug market are focusing on adoption of growth strategies such as product approvals which is expected to drive the market growth during the forecast period. For instance, in July 2018, Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced that the U.S. Food and Drug Administration had granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis. Moreover, increasing research and development activities by key players for the treatment of dermatomyositis which is expected to drive the market growth over the forecast period. For instance, on October 21, 2019, CSL Behring,a biopharmaceutical company initiated phase 3 Study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in adults with dermatomyositis (DM). The study is estimated to be completed in February 2024.

Key features of the study:

This report provides an in-depth analysis of the global dermatomyositis drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dermatomyositis drug market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceuticals USA, Inc., Hikma Pharmaceuticals PLC, Asahi Kasei Corporation., Octapharma USA, Healthcare Pharmaceuticals Limited., Zydus Cadila, Alkem Laboratories Ltd, Apotex Inc, Eli Lilly and Co, and F.Hoffman-La Roche Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dermatomyositis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis drug market

Detailed Segmentation:

Global Dermatomyositis Drug Market, By Drug Type:
- Corticosteroids
- Immunosuppressive Agents
- Others
Global Dermatomyositis Drug Market, By Route of Administration:
- Oral
- Topical
- Others
Global Dermatomyositis Drug Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Dermatomyositis Drug Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- Pfizer Inc *
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceuticals USA, Inc.
- Hikma Pharmaceuticals PLC
- Asahi Kasei Corporation
- Octapharma USA
- Healthcare Pharmaceuticals Limited
- Zydus Cadila
- Alkem Laboratories Ltd
- Apotex Inc
- Eli Lilly and Co
- F.Hoffman-La Roche Ltd

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channels
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Regulatory Scenario
Market Trends
Key Developments
Epidemiology
PEST Analysis
Collaboration and Acquisition
Porters Analysis
Pipeline Analysis

4. Global Dermatomyositis Drug Market - Impact of Coronavirus (COVID-19) Pandemic

Economic Impact
Impact on Demand and Supply
COVID-19 Impact Assessments

5. Global Dermatomyositis Drug Market, By Drug Type, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Immunosuppressive Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Dermatomyositis Drug Market, By Route of Administration, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

7. Global Dermatomyositis Drug Market, By Distribution Channel, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

8. Global Dermatomyositis Drug Market, By Region, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
U.K.
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017-2030,(US$ Mn)
North Africa
Central Africa
South Africa